Finance

JD.com shares climb after announcing $5 billion share buyback, outperforming decline in Hang Seng

Products You May Like

In this article

JD.com set up an Innovative Retail division that houses its grocery business 7Fresh.
Bloomberg | Bloomberg | Getty Images

Hong Kong-listed shares of Chinese online retailer JD.com climbed 1.2% on Wednesday, outperforming the decline on the Hang Seng index after the firm announced a $5 billion buyback late Tuesday.

U.S. listed shares of the firm rose 2.24% on Tuesday after the announcement. Both JD.com’s Hong Kong and U.S. shares have dropped about 20% year to date.

In comparison, Hong Kong’s benchmark Hang Seng index was down about 0.82% Wednesday, but is up about 4% for the year so far.

Stock Chart IconStock chart icon

hide content

The announcement is JD.com’s second buyback this year, after announcing a $3 billion buyback in March.

In response to the move, Chelsey Tam, senior equity analyst at Morningstar, said that the decision to announce the share buyback is “not surprising.” She explained, “It is a common theme in China when share prices and growth are low.”

Tam also pointed to Vipshop, another Chinese e-commerce player that has increased its own share buyback program last week.

China’s e-commerce sector has been dogged by a slow domestic economy.

Earlier this month, Alibaba’s second-quarter results missed expectations on both the top and bottom lines. On Monday, Temu-owner Pinduoduo saw its worst ever session after its second-quarter results missed both revenue and earnings per share expectations.

Back in February, Alibaba announced a $25 billion share buyback after it missed revenue targets for the fourth quarter of 2023.

Products You May Like

Articles You May Like

Kamala Harris Tax Plan Ideas: Details and Analysis
Boeing warns strike will ‘jeopardize’ recovery, hurt aircraft production
Apple is in talks with JPMorgan for bank to take over card from Goldman Sachs
This ‘back of the napkin math’ shows whether you could have a surprise tax bill, expert says
Pfizer says its experimental drug for deadly condition that causes appetite and weight loss in cancer patients shows positive trial results

Leave a Reply

Your email address will not be published. Required fields are marked *